APTEVO THERAP.INC.DL-,001

Aptevo Therapeutics' stock jumped after the company reported a 100% complete remission rate for the third cohort of its Phase‑1b/2 RAINIER study in newly diagnosed AML. Mipletamig in combination with venetoclax and azacitidine showed no dose‑limiting toxicities or cytokine release syndrome, and 40% of patients achieved MRD negativity. Enrollment for cohort 3 is complete, cohort 4 is being recruited at the next dose level, and results are expected to be presented at a major medical conference in the fourth quarter. » Plus sur de.investing.com

Aptevo announces two new trispecific therapy candidates: APVO452 (PSMA x CD3 x CD40) for prostate cancer and APVO451 (Nectin‑4 x CD3 x CD40) for various solid tumors. Both are built on the ADAPTIR‑FLEX platform and are designed to activate T cells in a tumor-specific manner and modulate the immunosuppressive tumor microenvironment; preclinical data show APVO452 activated the immune system only in the presence of tumor cells. Aptevo holds provisional patents for both candidates, bringing its pipeline to eight bispecific and trispecific programs, and notes negative EBITDA for the past twelve months. The company also reports it has regained compliance with NASDAQ listing requirements following a capital raise and a completed direct offering. » Plus sur de.investing.com

Aptevo Therapeutics released results for the quarter ended June 30, 2025, reporting a loss per share of $8.40. In the year-earlier period, EPS was -$1,235.80. » Plus sur finanzen.net